BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller SM, Cybulski V, Whitacre M, Bess LS, Livesay MT, Walsh L, Burkhart D, Bazin HG, Evans JT. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice. Front Immunol 2020;11:406. [PMID: 32210973 DOI: 10.3389/fimmu.2020.00406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Teng C, Meng X, Hu Y, Mao H, Li H, Yang J, Sun T, Meng S, Zong C. Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer. Polymers (Basel) 2022;14. [PMID: 36559833 DOI: 10.3390/polym14245466] [Reference Citation Analysis]
2 Valenzuela-Fernández A, Cabrera-Rodriguez R, Ciuffreda L, Perez-Yanes S, Estevez-Herrera J, González-Montelongo R, Alcoba-Florez J, Trujillo-González R, García-Martínez de Artola D, Gil-Campesino H, Díez-Gil O, Lorenzo-Salazar JM, Flores C, Garcia-Luis J. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Front Bioeng Biotechnol 2022;10:1052436. [PMID: 36507266 DOI: 10.3389/fbioe.2022.1052436] [Reference Citation Analysis]
3 Dowling DJ, Barman S, Smith AJ, Borriello F, Chaney D, Brightman SE, Melhem G, Brook B, Menon M, Soni D, Schüller S, Siram K, Nanishi E, Bazin HG, Burkhart DJ, Levy O, Evans JT. Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination. Sci Rep 2022;12:16860. [PMID: 36258023 DOI: 10.1038/s41598-022-20346-w] [Reference Citation Analysis]
4 Joseph J. Harnessing Nasal Immunity with IgA to Prevent Respiratory Infections. Immuno 2022;2:571-583. [DOI: 10.3390/immuno2040036] [Reference Citation Analysis]
5 Good MR, Guthmiller JJ. Female Antibodies Go the Distance against Influenza Viruses. mBio 2022;:e0210622. [PMID: 36094090 DOI: 10.1128/mbio.02106-22] [Reference Citation Analysis]
6 Jena AB, Duttaroy AK. A Computational Approach for Molecular Characterization of Covaxin (BBV152) and Its Ingredients for Assessing Its Efficacy against COVID-19. Future Pharmacology 2022;2:306-319. [DOI: 10.3390/futurepharmacol2030021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee G, Kang HR, Kim A, Park JH, Lee MJ, Kim SM. Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and invivo. Antiviral Res 2022;205:105384. [PMID: 35863499 DOI: 10.1016/j.antiviral.2022.105384] [Reference Citation Analysis]
8 Kong D, Chen T, Hu X, Lin S, Gao Y, Ju C, Liao M, Fan H. Supplementation of H7N9 Virus-Like Particle Vaccine With Recombinant Epitope Antigen Confers Full Protection Against Antigenically Divergent H7N9 Virus in Chickens. Front Immunol 2022;13:785975. [PMID: 35265069 DOI: 10.3389/fimmu.2022.785975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Noh K, Jeong EJ, An T, Shin JS, Kim H, Han SB, Kim M. The efficacy of a 2,4-diaminoquinazoline compound as an intranasal vaccine adjuvant to protect against influenza A virus infection in vivo. J Microbiol 2022;60:550-559. [DOI: 10.1007/s12275-022-1661-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Dhume K, Finn CM, Devarajan P, Singh A, Tejero JD, Prokop E, Strutt TM, Sell S, Swain SL, Mckinstry KK. Bona Fide Th17 Cells without Th1 Functional Plasticity Protect against Influenza. J I 2022;208:1998-2007. [DOI: 10.4049/jimmunol.2100801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Akache B, Stark FC, Agbayani G, Renner TM, McCluskie MJ. Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines. Methods Mol Biol 2022;2412:179-231. [PMID: 34918246 DOI: 10.1007/978-1-0716-1892-9_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chatzikleanthous D, O'Hagan DT, Adamo R. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. Mol Pharm 2021;18:2867-88. [PMID: 34264684 DOI: 10.1021/acs.molpharmaceut.1c00447] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
13 Zenobia C, Herpoldt KL, Freire M. Is the oral microbiome a source to enhance mucosal immunity against infectious diseases? NPJ Vaccines 2021;6:80. [PMID: 34078913 DOI: 10.1038/s41541-021-00341-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, Kannappa SV, Ella KM, Ravikrishnan R, Awasthi A, Jose J, Rao P, Kumar D, Ella R, Abraham P, Yadav PD, Sapkal GN, Shete-Aich A, Desphande G, Mohandas S, Basu A, Gupta N, Vadrevu KM. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience 2021;24:102298. [PMID: 33723528 DOI: 10.1016/j.isci.2021.102298] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 21.0] [Reference Citation Analysis]
15 Owen AM, Fults JB, Patil NK, Hernandez A, Bohannon JK. TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. Front Immunol 2020;11:622614. [PMID: 33679711 DOI: 10.3389/fimmu.2020.622614] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
16 Andrianov AK, Langer R. Polyphosphazene immunoadjuvants: Historical perspective and recent advances. J Control Release 2021;329:299-315. [PMID: 33285104 DOI: 10.1016/j.jconrel.2020.12.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
17 Liao K, Niu F, Hu G, Yang L, Dallon B, Villarreal D, Buch S. Morphine-mediated release of miR-138 in astrocyte-derived extracellular vesicles promotes microglial activation. J Extracell Vesicles 2020;10:e12027. [PMID: 33304479 DOI: 10.1002/jev2.12027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
18 Auderset F, Belnoue E, Mastelic-Gavillet B, Lambert PH, Siegrist CA. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner. Front Immunol 2020;11:580974. [PMID: 33262759 DOI: 10.3389/fimmu.2020.580974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Federico S, Pozzetti L, Papa A, Carullo G, Gemma S, Butini S, Campiani G, Relitti N. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. J Med Chem 2020;63:13466-513. [PMID: 32845153 DOI: 10.1021/acs.jmedchem.0c01049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
20 Kim WS, Han JM, Song HY, Byun EH, Lim ST, Byun EB. Annona muricata L.-Derived Polysaccharides as a Potential Adjuvant to a Dendritic Cell-Based Vaccine in a Thymoma-Bearing Model. Nutrients 2020;12:E1602. [PMID: 32486094 DOI: 10.3390/nu12061602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]